HC Wainwright started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Thursday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $33.00 price objective on the biopharmaceutical company’s stock.
Several other equities research analysts also recently weighed in on MRNS. ValuEngine downgraded shares of Marinus Pharmaceuticals from a hold rating to a sell rating in a report on Friday, December 1st. BidaskClub downgraded shares of Marinus Pharmaceuticals from a buy rating to a hold rating in a report on Thursday, December 7th. Finally, Laidlaw initiated coverage on shares of Marinus Pharmaceuticals in a report on Thursday, December 14th. They issued a buy rating and a $18.00 price objective for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $20.67.
Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) opened at $6.22 on Thursday. Marinus Pharmaceuticals has a 1-year low of $1.13 and a 1-year high of $9.87.
Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp acquired a new stake in Marinus Pharmaceuticals in the 3rd quarter valued at about $128,000. FNY Partners Fund LP acquired a new stake in Marinus Pharmaceuticals in the 4th quarter valued at about $183,000. Wells Fargo & Company MN acquired a new stake in Marinus Pharmaceuticals in the 4th quarter valued at about $225,000. Citadel Advisors LLC lifted its holdings in Marinus Pharmaceuticals by 327.8% in the 3rd quarter. Citadel Advisors LLC now owns 51,383 shares of the biopharmaceutical company’s stock valued at $301,000 after acquiring an additional 39,371 shares during the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in Marinus Pharmaceuticals in the 4th quarter valued at about $305,000. 52.58% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “HC Wainwright Initiates Coverage on Marinus Pharmaceuticals (MRNS)” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.chaffeybreeze.com/2018/02/18/hc-wainwright-initiates-coverage-on-marinus-pharmaceuticals-mrns.html.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.